Results 161 to 170 of about 2,285,787 (260)

Chimeric antigen receptor T-cells in multiple myeloma: Present and future [PDF]

This is a brief summary of various general contemporary topics regarding chimeric antigen receptor (CAR) T-cells in multiple myeloma (MM)
Plata, Carlos
core  

A novel Chimeric Antigen Receptor (CAR) - strategy to target EGFR^VIII-mutated glioblastoma cells via macrophages. [PDF]

BMC Cancer
Vera K, Esken G, Hwang JW, Elbaz C, Chaker D, Oudrhiri N, Desterke C, Griscelli F, Bennaceur-Griscelli A, Turhan AG.   +9 more
europepmc   +1 more source

Chimeric antigen receptor (CAR) therapies for precise eradication of pathogenic cells in autoimmunity. [PDF]

Arthritis Res Ther
Kalliolias GD, Basdra EK, Papavassiliou AG.   +2 more
europepmc   +1 more source

Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting. [PDF]

Br J Haematol
Villeneuve PJA, Mozessohn L, Somé NH, Mercer RE, Masucci L, Kouroukis T, Bredeson C, Aktar S, Guan Q, Prica A, Chen CI, Rodin D, Cheung M, Chaudhry M, Gavura S, McKay C, Wong WWL, Chan KKW.   +17 more
europepmc   +1 more source

Advancing Cancer Immunotherapy: Chimeric Antigen Receptor (CAR)-T Cell Engineering through Novel Screening Methods. [PDF]

Biomol Ther (Seoul)
Ha J, Seong J.
europepmc   +1 more source

Chimeric antigen receptor (CAR) -T cell therapy treatment Richter's transformation. [PDF]

Front Oncol
Feng S, Zheng P, Liu H, Sun M, Guo Y, Ma L, Liu R, Fu Z, Yang F, Ke X, Hu K.   +10 more
europepmc   +1 more source

Chimeric Antigen Receptor (CAR) T Cell Therapy for Neuromuscular Disorders: A Systematic Review. [PDF]

Cureus
Finsterer J.
europepmc   +1 more source

Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review. [PDF]

Pharmacoecon Open
Patel N, Farid S, Gomes M.
europepmc   +1 more source

Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy vs. CD20xCD3 bispecific antibody as third- or later-line treatment in follicular lymphoma: a meta-analysis. [PDF]

Ann Hematol
Li X, Liao J, Liu S, Mo X, Wang B.
europepmc   +1 more source

Lymphoid and Myeloid Proliferations After Chimeric Antigen Receptor (CAR) T-Cell Therapy: The Pathologist's Perspective. [PDF]

Int J Mol Sci
Zhou J, Kelemen K.
europepmc   +1 more source